Guest guest Posted January 23, 2008 Report Share Posted January 23, 2008 IM not sure hon,, maybe liz can answer that, but at the very least, they could transfuse you with more blood which would have more platelets joyceann wrote: i have a question, if my platletts keep decreasing (another blood test tommorrow) what do they do for that?????Jackie Quote Link to comment Share on other sites More sharing options...
Guest guest Posted January 23, 2008 Report Share Posted January 23, 2008 The nurse educator at the GI clinic I go to said that giving platelets wasn't an option if levels went too low as they would be absorbed within twenty four hours. I saw her today to get a final rundown on things before starting first day of treatment Friday. Fingers crossed. Mike iJackie on wrote: IM not sure hon,, maybe liz can answer that, but at the very least, they could transfuse you with more blood which would have more platelets joyceann <mepurplegee> wrote: i have a question, if my platletts keep decreasing (another blood test tommorrow) what do they do for that?????Jackie Never miss a thing. Make Yahoo your homepage. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted January 23, 2008 Report Share Posted January 23, 2008 Keeping fingers crossed and hopeing all will be ok,, keep us posted,, and thanks for the info regarding no transfusing platelets, I had no idea,, so thank you,, m human wrote: The nurse educator at the GI clinic I go to said that giving platelets wasn't an option if levels went too low as they would be absorbed within twenty four hours. I saw her today to get a final rundown on things before starting first day of treatment Friday. Fingers crossed. Mike iJackie on <redjaxjm> wrote: IM not sure hon,, maybe liz can answer that, but at the very least, they could transfuse you with more blood which would have more platelets joyceann <mepurplegee> wrote: i have a question, if my platletts keep decreasing (another blood test tommorrow) what do they do for that?????Jackie Never miss a thing. Make Yahoo your homepage. Jackie Quote Link to comment Share on other sites More sharing options...
Guest guest Posted January 23, 2008 Report Share Posted January 23, 2008 There is nothing right now except transfusion or eltrombopag but that is still in the clinical studies Re: decreased plateletts IM not sure hon,, maybe liz can answer that, but at the very least, they could transfuse you with more blood which would have more platelets joyceann <mepurplegee> wrote: i have a question, if my platletts keep decreasing (another blood test tommorrow) what do they do for that?????Jackie Quote Link to comment Share on other sites More sharing options...
Guest guest Posted January 24, 2008 Report Share Posted January 24, 2008 well I KNEW that YOU would know Liz,, thanks for the info, I've never heard of that drug,, how much into studies is it? How much longer do you think it will be before it will be out there IF its successful? elizabethnv1 wrote: There is nothing right now except transfusion or eltrombopag but that is still in the clinical studies Re: decreased plateletts IM not sure hon,, maybe liz can answer that, but at the very least, they could transfuse you with more blood which would have more platelets joyceann <mepurplegee> wrote: i have a question, if my platletts keep decreasing (another blood test tommorrow) what do they do for that?????Jackie Jackie Quote Link to comment Share on other sites More sharing options...
Guest guest Posted January 24, 2008 Report Share Posted January 24, 2008 Eltrombopag Improves Thrombocytopenia in Patients with Cirrhosis Thrombocytopenia, or low platelet count, can lead to easy bruising and prolonged bleeding. People with advanced fibrosis or cirrhosis, who may develop portal hypertension and reduced synthesis of blood clotting factors, often develop thrombocytopenia. The condition can also be a side effect of treatment with interferon, and patients with pre-existing thrombocytopenia are typically advised against using interferon-based therapy.Research has shown that blood cell growth factors can help manage the hematological side effects of HCV treatment. Use of granulocyte colony-stimulating factor (G-CSF) for interferon-induced neutropenia and erythropoietin (EPO) for ribavirin-induced anemia can help patients stay on full-dose hepatitis C therapy. At the recent Digestive Disease Week conference in Los Angeles, McHutchison, MD, presented promising safety, efficacy, and tolerability data for a new oral blood platelet growth factor, eltrombopag (SB-497115).In this double-blind multicenter Phase II study, 33 chronic hepatitis C patients with compensated cirrhosis and baseline platelet counts between 20,000 and 70,000/microliter (mcL) were randomly allocated into four arms: 30 mg once-daily eltrombopag 50 mg once-daily eltrombopag 75 mg once-daily eltrombopag Placebo Therapy continued for four weeks. Patients who achieved platelet counts greater than 70,000/mcL after the 28 days were then eligible to start treatment with pegylated interferon plus ribavirin, while eltrombopag was continued. Results After 28 days, the proportion of responders, defined as achieving a platelet count ? 100,000/mcL, was higher in all eltrombopag dose groups compared with placebo. The highest response rate was observed in the 75 mg eltrombopag group, with 9 out of 10 responders (90%); there were no responders in the placebo arm. After 28 days, median platelet counts were higher in the eltrombopag groups than in the placebo group. No serious adverse events were reported in any group, and no discontinuations occurred due to side effects. The most common side effects were fever, chills, flu-like symptoms, and headaches. Placebo n=5 30mg n=8 50mg n=9 75mg n=11 Age (median, years) 54 49 56 51 Gender, male (n, %) 3/5 (60%) 7/8 (88%) 6/9 (67%) 8/11 (73%) Responders at Day 28* (n, %) 0/5 4/6 (67%) 7/9 (78%) 9/10 (90%) Platelet count at baseline, x103/ul (median, min/max) 47 (38,62) 61 (42,94) 45 (26,66) 56 (28,75) Platelet count at Day 28, x103/ul (median, min/max) 38 (34,55) 119 (58,214) 174 (47,252) 246 (78,478) Subjects who experienced an AE (n, %) 3/5 (60%) 7/8 (88%) 7/9 (78%) 9/11 (82%) * proportion of evaluable subjects with an increase in platelet count from baseline to > 100,000/mcL after four weeks of SB-497115 treatment ConclusionThe researchers concluded that the limited interim data from this ongoing study show that eltrombopag can increase platelet counts and enable the initiation of treatment with pegylated interferon in subjects with HCV-related cirrhosis and associated thrombocytopenia.6/09/06 Re: decreased plateletts IM not sure hon,, maybe liz can answer that, but at the very least, they could transfuse you with more blood which would have more platelets joyceann <mepurplegee> wrote: i have a question, if my platletts keep decreasing (another blood test tommorrow) what do they do for that?????Jackie Jackie Quote Link to comment Share on other sites More sharing options...
Guest guest Posted January 24, 2008 Report Share Posted January 24, 2008 Re: decreased plateletts IM not sure hon,, maybe liz can answer that, but at the very least, they could transfuse you with more blood which would have more platelets joyceann <mepurplegee> wrote: i have a question, if my platletts keep decreasing (another blood test tommorrow) what do they do for that?????Jackie Jackie Quote Link to comment Share on other sites More sharing options...
Guest guest Posted January 25, 2008 Report Share Posted January 25, 2008 thanls i get my blood results today, hopefully it hasnt gone any lower elizabethnv1 wrote: Eltrombopag Improves Thrombocytopenia in Patients with Cirrhosis Thrombocytopenia, or low platelet count, can lead to easy bruising and prolonged bleeding. People with advanced fibrosis or cirrhosis, who may develop portal hypertension and reduced synthesis of blood clotting factors, often develop thrombocytopenia. The condition can also be a side effect of treatment with interferon, and patients with pre-existing thrombocytopenia are typically advised against using interferon-based therapy.Research has shown that blood cell growth factors can help manage the hematological side effects of HCV treatment. Use of granulocyte colony-stimulating factor (G-CSF) for interferon-induced neutropenia and erythropoietin (EPO) for ribavirin-induced anemia can help patients stay on full-dose hepatitis C therapy. At the recent Digestive Disease Week conference in Los Angeles, McHutchison, MD, presented promising safety, efficacy, and tolerability data for a new oral blood platelet growth factor, eltrombopag (SB-497115).In this double-blind multicenter Phase II study, 33 chronic hepatitis C patients with compensated cirrhosis and baseline platelet counts between 20,000 and 70,000/microliter (mcL) were randomly allocated into four arms: 30 mg once-daily eltrombopag 50 mg once-daily eltrombopag 75 mg once-daily eltrombopag Placebo Therapy continued for four weeks. Patients who achieved platelet counts greater than 70,000/mcL after the 28 days were then eligible to start treatment with pegylated interferon plus ribavirin, while eltrombopag was continued. Results After 28 days, the proportion of responders, defined as achieving a platelet count ? 100,000/mcL, was higher in all eltrombopag dose groups compared with placebo. The highest response rate was observed in the 75 mg eltrombopag group, with 9 out of 10 responders (90%); there were no responders in the placebo arm. After 28 days, median platelet counts were higher in the eltrombopag groups than in the placebo group. No serious adverse events were reported in any group, and no discontinuations occurred due to side effects. The most common side effects were fever, chills, flu-like symptoms, and headaches. Placebo n=5 30mg n=8 50mg n=9 75mg n=11 Age (median, years) 54 49 56 51 Gender, male (n, %) 3/5 (60%) 7/8 (88%) 6/9 (67%) 8/11 (73%) Responders at Day 28* (n, %) 0/5 4/6 (67%) 7/9 (78%) 9/10 (90%) Platelet count at baseline, x103/ul (median, min/max) 47 (38,62) 61 (42,94) 45 (26,66) 56 (28,75) Platelet count at Day 28, x103/ul (median, min/max) 38 (34,55) 119 (58,214) 174 (47,252) 246 (78,478) Subjects who experienced an AE (n, %) 3/5 (60%) 7/8 (88%) 7/9 (78%) 9/11 (82%) * proportion of evaluable subjects with an increase in platelet count from baseline to > 100,000/mcL after four weeks of SB-497115 treatment ConclusionThe researchers concluded that the limited interim data from this ongoing study show that eltrombopag can increase platelet counts and enable the initiation of treatment with pegylated interferon in subjects with HCV-related cirrhosis and associated thrombocytopenia.6/09/06 Re: decreased plateletts IM not sure hon,, maybe liz can answer that, but at the very least, they could transfuse you with more blood which would have more platelets joyceann <mepurplegee> wrote: i have a question, if my platletts keep decreasing (another blood test tommorrow) what do they do for that?????Jackie Jackie Be a better friend, newshound, and know-it-all with Yahoo! Mobile. Try it now. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted January 25, 2008 Report Share Posted January 25, 2008 Go to the NIH site and do a search for eltrombopag. There is a list of stage III clinical trials that are recruiting or will be very soon. Re: decreased plateletts Eltrombopag Improves Thrombocytopenia in Patients with Cirrhosis Thrombocytopenia, or low platelet count, can lead to easy bruising and prolonged bleeding. People with advanced fibrosis or cirrhosis, who may develop portal hypertension and reduced synthesis of blood clotting factors, often develop thrombocytopenia. The condition can also be a side effect of treatment with interferon, and patients with pre-existing thrombocytopenia are typically advised against using interferon-based therapy. Research has shown that blood cell growth factors can help manage the hematological side effects of HCV treatment. Use of granulocyte colony-stimulating factor (G-CSF) for interferon-induced neutropenia and erythropoietin (EPO) for ribavirin-induced anemia can help patients stay on full-dose hepatitis C therapy. At the recent Digestive Disease Week conference in Los Angeles, McHutchison, MD, presented promising safety, efficacy, and tolerability data for a new oral blood platelet growth factor, eltrombopag (SB-497115). In this double-blind multicenter Phase II study, 33 chronic hepatitis C patients with compensated cirrhosis and baseline platelet counts between 20,000 and 70,000/microliter (mcL) were randomly allocated into four arms: 30 mg once-daily eltrombopag 50 mg once-daily eltrombopag 75 mg once-daily eltrombopag Placebo Therapy continued for four weeks. Patients who achieved platelet counts greater than 70,000/mcL after the 28 days were then eligible to start treatment with pegylated interferon plus ribavirin, while eltrombopag was continued. Results After 28 days, the proportion of responders, defined as achieving a platelet count ? 100,000/mcL, was higher in all eltrombopag dose groups compared with placebo. The highest response rate was observed in the 75 mg eltrombopag group, with 9 out of 10 responders (90%); there were no responders in the placebo arm. After 28 days, median platelet counts were higher in the eltrombopag groups than in the placebo group. No serious adverse events were reported in any group, and no discontinuations occurred due to side effects. The most common side effects were fever, chills, flu-like symptoms, and headaches. Placebo n=5 30mg n=8 50mg n=9 75mg n=11 Age (median, years) 54 49 56 51 Gender, male (n, %) 3/5 (60%) 7/8 (88%) 6/9 (67%) 8/11 (73%) Responders at Day 28* (n, %) 0/5 4/6 (67%) 7/9 (78%) 9/10 (90%) Platelet count at baseline, x103/ul (median, min/max) 47 (38,62) 61 (42,94) 45 (26,66) 56 (28,75) Platelet count at Day 28, x103/ul (median, min/max) 38 (34,55) 119 (58,214) 174 (47,252) 246 (78,478) Subjects who experienced an AE (n, %) 3/5 (60%) 7/8 (88%) 7/9 (78%) 9/11 (82%) * proportion of evaluable subjects with an increase in platelet count from baseline to > 100,000/mcL after four weeks of SB-497115 treatment Conclusion The researchers concluded that the limited interim data from this ongoing study show that eltrombopag can increase platelet counts and enable the initiation of treatment with pegylated interferon in subjects with HCV-related cirrhosis and associated thrombocytopenia. 6/09/06 Re: decreased plateletts IM not sure hon,, maybe liz can answer that, but at the very least, they could transfuse you with more blood which would have more platelets joyceann <mepurplegee> wrote: i have a question, if my platletts keep decreasing (another blood test tommorrow) what do they do for that????? Jackie Jackie More new features than ever. Check out the new AOL Mail! Quote Link to comment Share on other sites More sharing options...
Guest guest Posted January 25, 2008 Report Share Posted January 25, 2008 -liz is this something my dr would know about,,,,i wanna finish my hep tx only on week 3 and now the platlett prob and wbc,-- In Hepatitis_C_Central , " elizabethnv1 " wrote: > > Eltrombopag Improves Thrombocytopenia in Patients with Cirrhosis > Thrombocytopenia, or low platelet count, can lead to easy bruising and prolonged bleeding. People with advanced fibrosis or cirrhosis, who may develop portal hypertension and reduced synthesis of blood clotting factors, often develop thrombocytopenia. The condition can also be a side effect of treatment with interferon, and patients with pre-existing thrombocytopenia are typically advised against using interferon-based therapy. > > Research has shown that blood cell growth factors can help manage the hematological side effects of HCV treatment. Use of granulocyte colony-stimulating factor (G-CSF) for interferon-induced neutropenia and erythropoietin (EPO) for ribavirin-induced anemia can help patients stay on full-dose hepatitis C therapy. > > At the recent Digestive Disease Week conference in Los Angeles, McHutchison, MD, presented promising safety, efficacy, and tolerability data for a new oral blood platelet growth factor, eltrombopag (SB-497115). > > In this double-blind multicenter Phase II study, 33 chronic hepatitis C patients with compensated cirrhosis and baseline platelet counts between 20,000 and 70,000/microliter (mcL) were randomly allocated into four arms: > > > 30 mg once-daily eltrombopag > 50 mg once-daily eltrombopag > 75 mg once-daily eltrombopag > Placebo > > > Therapy continued for four weeks. Patients who achieved platelet counts greater than 70,000/mcL after the 28 days were then eligible to start treatment with pegylated interferon plus ribavirin, while eltrombopag was continued. > > Results > > > After 28 days, the proportion of responders, defined as achieving a platelet count ? 100,000/mcL, was higher in all eltrombopag dose groups compared with placebo. > The highest response rate was observed in the 75 mg eltrombopag group, with 9 out of 10 responders (90%); there were no responders in the placebo arm. > After 28 days, median platelet counts were higher in the eltrombopag groups than in the placebo group. > No serious adverse events were reported in any group, and no discontinuations occurred due to side effects. > The most common side effects were fever, chills, flu- like symptoms, and headaches. > > > > Placebo > n=5 > 30mg > n=8 > 50mg > n=9 > 75mg > n=11 > > Age > (median, years) > 54 > 49 > 56 > 51 > > Gender, male > (n, %) > 3/5 > (60%) > 7/8 > (88%) > 6/9 > (67%) > 8/11 > (73%) > > Responders at Day 28* > (n, %) > 0/5 > 4/6 > (67%) > 7/9 > (78%) > 9/10 > (90%) > > Platelet count at baseline, x103/ul > (median, min/max) > 47 > (38,62) > 61 > (42,94) > 45 > (26,66) > 56 > (28,75) > > Platelet count at Day 28, x103/ul > (median, min/max) > 38 > (34,55) > 119 > (58,214) > 174 > (47,252) > 246 > (78,478) > > Subjects who experienced an AE > (n, %) > 3/5 > (60%) > 7/8 > (88%) > 7/9 > (78%) > 9/11 > (82%) > > * proportion of evaluable subjects with an increase in platelet count from baseline to > 100,000/mcL after four weeks of SB- 497115 treatment > > > > Conclusion > > The researchers concluded that the limited interim data from this ongoing study show that eltrombopag can increase platelet counts and enable the initiation of treatment with pegylated interferon in subjects with HCV-related cirrhosis and associated thrombocytopenia. > > 6/09/06 > > Re: decreased plateletts > > > IM not sure hon,, maybe liz can answer that, but at the very least, they could transfuse you with more blood which would have more platelets > > > > > joyceann wrote: > i have a question, if my platletts keep decreasing (another blood test > tommorrow) what do they do for that????? > > > > > > > Jackie > > > > > Jackie > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted January 25, 2008 Report Share Posted January 25, 2008 ill go check it outalfonset@... wrote: Go to the NIH site and do a search for eltrombopag. There is a list of stage III clinical trials that are recruiting or will be very soon. Re: decreased plateletts Eltrombopag Improves Thrombocytopenia in Patients with Cirrhosis Thrombocytopenia, or low platelet count, can lead to easy bruising and prolonged bleeding. People with advanced fibrosis or cirrhosis, who may develop portal hypertension and reduced synthesis of blood clotting factors, often develop thrombocytopenia. The condition can also be a side effect of treatment with interferon, and patients with pre-existing thrombocytopenia are typically advised against using interferon-based therapy.Research has shown that blood cell growth factors can help manage the hematological side effects of HCV treatment. Use of granulocyte colony-stimulating factor (G-CSF) for interferon-induced neutropenia and erythropoietin (EPO) for ribavirin-induced anemia can help patients stay on full-dose hepatitis C therapy. At the recent Digestive Disease Week conference in Los Angeles, McHutchison, MD, presented promising safety, efficacy, and tolerability data for a new oral blood platelet growth factor, eltrombopag (SB-497115).In this double-blind multicenter Phase II study, 33 chronic hepatitis C patients with compensated cirrhosis and baseline platelet counts between 20,000 and 70,000/microliter (mcL) were randomly allocated into four arms: 30 mg once-daily eltrombopag 50 mg once-daily eltrombopag 75 mg once-daily eltrombopag Placebo Therapy continued for four weeks. Patients who achieved platelet counts greater than 70,000/mcL after the 28 days were then eligible to start treatment with pegylated interferon plus ribavirin, while eltrombopag was continued. Results After 28 days, the proportion of responders, defined as achieving a platelet count ? 100,000/mcL, was higher in all eltrombopag dose groups compared with placebo. The highest response rate was observed in the 75 mg eltrombopag group, with 9 out of 10 responders (90%); there were no responders in the placebo arm. After 28 days, median platelet counts were higher in the eltrombopag groups than in the placebo group. No serious adverse events were reported in any group, and no discontinuations occurred due to side effects. The most common side effects were fever, chills, flu-like symptoms, and headaches. Placebo n=5 30mg n=8 50mg n=9 75mg n=11 Age (median, years) 54 49 56 51 Gender, male (n, %) 3/5 (60%) 7/8 (88%) 6/9 (67%) 8/11 (73%) Responders at Day 28* (n, %) 0/5 4/6 (67%) 7/9 (78%) 9/10 (90%) Platelet count at baseline, x103/ul (median, min/max) 47 (38,62) 61 (42,94) 45 (26,66) 56 (28,75) Platelet count at Day 28, x103/ul (median, min/max) 38 (34,55) 119 (58,214) 174 (47,252) 246 (78,478) Subjects who experienced an AE (n, %) 3/5 (60%) 7/8 (88%) 7/9 (78%) 9/11 (82%) * proportion of evaluable subjects with an increase in platelet count from baseline to > 100,000/mcL after four weeks of SB-497115 treatment ConclusionThe researchers concluded that the limited interim data from this ongoing study show that eltrombopag can increase platelet counts and enable the initiation of treatment with pegylated interferon in subjects with HCV-related cirrhosis and associated thrombocytopenia.6/09/06 Re: decreased plateletts IM not sure hon,, maybe liz can answer that, but at the very least, they could transfuse you with more blood which would have more platelets joyceann <mepurplegee> wrote: i have a question, if my platletts keep decreasing (another blood test tommorrow) what do they do for that?????Jackie Jackie More new features than ever. Check out the new AOL Mail! Never miss a thing. Make Yahoo your homepage. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted January 28, 2008 Report Share Posted January 28, 2008 Usually for depleted platlete count, the only alternative is an infusion of platletes or whole blood. This will probably be done at your local hospital as an out patient. Steve B... Never miss a thing. Make Yahoo your homepage. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted January 28, 2008 Report Share Posted January 28, 2008 hi steve, thanks for yr input i appreciate it very very much i belive you are right, ive been looking around for myself and seems infusion is the answer, you could imagine, i am of course scared a transfusion wow, but i really dont what other alternative there is, thanks and any info you can supply is much appreciatedSteve Bridgers wrote: Usually for depleted platlete count, the only alternative is an infusion of platletes or whole blood. This will probably be done at your local hospital as an out patient. Steve B... Never miss a thing. Make Yahoo your homepage. Never miss a thing. Make Yahoo your homepage. Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.